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Abstract: The dysregulation of microRNA (miRNA) is implicated in cancer, inflammation, cardio-
vascular disorders, drug resistance, and aging. While most researchers study miRNA’s role as
a biomarker, for example, to distinguish between various sub-forms or stages of a given disease of
interest, research is also ongoing to utilize these small nucleic acids as therapeutics. An example of
a common pleiotropic disease that could benefit from miRNA-based therapeutics is inflammatory
bowel disease (IBD), which is characterized by chronic inflammation of the small and large intestines.
Due to complex interactions between multiple factors in the etiology of IBD, development of ther-
apies that effectively maintain remission for this disease is a significant challenge. In this review,
we discuss the role of dysregulated miRNA expression in the context of clinical ulcerative colitis
(UC) and Crohn’s disease (CD)—the two main forms of IBD—and the various preclinical mouse
models of IBD utilized to validate the therapeutic potential of targeting these miRNA. Additionally,
we highlight advances in the development of genetically engineered animal models that recapitulate
clinical miRNA expression and provide powerful preclinical models to assess the diagnostic and
therapeutic promise of miRNA in IBD.
Keywords: miRNA; IBD; ulcerative colitis (UC); Crohn’s disease (CD); genetic diversity; collaborative
cross; diversity outbred; humanized mice; extracellular vesicles
1. Introduction
Inflammatory bowel disease (IBD) is a multifactorial progressive disease marked
by recurrent chronic inflammation of the gastrointestinal tract, a dysregulated immune
system, and dysbiosis [1–4]. IBD comprises two main forms—Crohn’s disease (CD) [5] and
ulcerative colitis (UC) [6,7]. Abdominal pain, chronic diarrhea, weight loss, exhaustion,
and anorexia are common symptoms among younger CD patients. Bloody diarrhea is
a symptom of chronic CD. Although the entire gastrointestinal tract can be impacted in CD
patients, the terminal ileum and colon are the most affected. Preferred therapeutic agents
for CD include immunosuppressants (e.g., azathioprine, mercaptopurine, and methotrex-
ate), corticosteroids, anti-TNF therapy (e.g., Adalimumab and Infliximab), monoclonal
antibodies (e.g., Vedolizumab and Ustekinumab), and surgery for patients who do not
respond to treatment [8,9]. In UC, only the colonic mucosa is inflamed, and the major symp-
toms include rectal tenesmus, bleeding, diarrhea, abdominal pain, and fecal incontinence.
Preferred therapeutic agents include, 5-Aminosalicylic acid (oral, suppository, or enema),
corticosteroids, anti-TNF agents (e.g., Infliximab, Golimumab, Adalimumab), and mon-
oclonal antibodies (e.g., Vedolizumab and Ustekinumab) [8,10]. In the United States,
approximately 3 million adults (>18 years of age) have IBD [11], and there is currently no
cure. The global prevalence of IBD is increasing [12,13], necessitating the development
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of innovative therapeutic strategies. The mechanisms underpinning IBD pathogenesis
are still emerging; nevertheless, a large body of evidence suggests that microRNAs play
a major role in IBD pathophysiology [14–16]. Here, we review clinically relevant miRNAs
that have been validated in various mouse models of IBD.
2. MicroRNA and IBD
Non-coding RNAs (ncRNA) are a subset of cellular RNAs that do not code for protein,
but ncRNAs play vital roles in regulating a multitude of cellular processes. According to the
Encyclopedia of DNA Elements (ENCODE) project and subsequent studies, approximately
20% of the human genome is not transcribed [17].
Based on function, ncRNAs are divided into housekeeping and regulatory ncRNAs.
Housekeeping ncRNAs include ribosomal RNA (rRNA), transfer RNA (tRNA), small
nuclear RNA (snRNA), small nucleolar RNA (snoRNA), telomerase RNA/tRNA-derived
fragments (TERC tRF), and tRNA halves (tiRNA). Housekeeping ncRNAs are expressed in
all cell types and are essential for cell viability through supporting RNA translation into
proteins and transcript splicing [18]. Regulatory ncRNAs are sub-classified on the basis
of size into small ncRNAs (sncRNAs), which are usually less than 200 nucleotides (nts) in
length, and long ncRNA (lncRNAs) greater than 200 nts [19]. sncRNAs include microRNA
(miRNA), small interfering RNA (siRNA), and piwi-interacting RNA (piRNA) [17]. Some
ncRNAs, such as enhancer RNA (eRNA), promoter-associated transcripts (PATs), and
circular RNAs (circRNAs), exhibit variable lengths and can hence be classified as either
sncRNAs or lncRNAs [17]. Regulatory ncRNAs play critical roles in modulating and
maintaining transcriptional and translational processes [20].
2.1. Synthesis and Physiological Significance of miRNA
The most widely studied ncRNA is miRNA. miRNA is 18–25 nts long with a primary
function in regulating post-transcriptional gene silencing by binding to the 3′-untranslated
regions (UTR) of messenger RNA (mRNA), thereby blocking translation. It is estimated
that over 60% of human coding genes are modulated by miRNAs at a translational level,
with about two-thirds of all protein-coding genes under pressure to maintain miRNA
pairing [21]. miRNA is promiscuous; a single miRNA typically regulates the translation of
multiple mRNAs. On the other hand, multiple different miRNAs may be required to block
the translation of a particular mRNA [22,23].
miRNA originates in the nucleus from the introns or exons of DNA, transcribed by
RNA polymerase II and III into a 1 kb long primary-miRNA (pri-miRNA) that contains
a hairpin-like structure [24]. Drosha and DGCR8 cleave the pri-miRNA into precursor-
miRNA (pre-RNA) approximately 70 nts long. The pre-miRNA is then transported out
of the nucleus with the help of Exportin 5. In the cytoplasm, the RNA-induced silencing
complex (RISC), which contains double-stranded RNA binding proteins including Dicer
and trans-activator RNA binding protein, cleaves the pre-miRNA into a short, 18–25 nt
long, double-stranded mature miRNA. The Argonaut 2 (Ago2) protein present in the RISC
holds on to the 5′ end of the miRNA strand, called the guide strand—the target strand
for the 3′ UTR of the mRNA. Next, RISC finds the target mRNA strand complementary
to the guide miRNA strand and, subsequently, either degrades or inhibits the translation
of the mRNA by binding to the ‘seed region’ spanning 2–8 bases from the 5′ end of the
miRNA [25]. Within the cytoplasm, miRNA functions are kept in check and regulated
by interactions with other ncRNAs. For example, the circRNA hsa_circ-0001368 binds to
miR-6506-5p, acting as a miRNA sponge that inhibits the miRNA’s suppression of the fork-
head family transcription factor FOXO3, thus functioning as a tumor suppressor in gastric
cancer [26]. As noted above, interactions between miRNA and mRNA lead to the blocking
of translation into protein. For example, miRNAs miR-122, -192, -495, and -671 bind to the
many 3′-UTRs of mRNA coding for nucleotide-binding oligomerization domain-containing
protein 2 (NOD2), also known as caspase recruitment domain-containing protein 15 or
inflammatory bowel disease protein 1 (IBD1). This binding represses NOD2 expression in
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response to inflammatory stimulation by muramyl dipeptide (MDP) in HCT116 cells [27].
These complex interactions of miRNA underscore its importance in determining cell fate,
enabling cells to navigate through their developmental stages and maintaining a cell at its
appropriate developmental stage [28,29].
2.2. Detection of miRNA
Ambros et al. have set out some identifiers for distinguishing miRNA from siRNA.
For miRNA specifically, two out of the following criteria should be met: (i) expression
criterion: the expression should be confirmed by tests, such as northern blot, or quantita-
tive real-time polymerase chain reaction (RT-qPCR); (ii) structure criterion: one arm of the
hairpin precursor must contain the miRNA structure; (iii) conservation criterion: phylo-
genetical conservation of sequences [30,31]. Since miRNA is being increasingly studied
to understand its functions in the normal state and as a disease biomarker, the improved
detection of miRNA is expected to aid in prognosis and in identifying disease-relevant,
putative therapeutic miRNA candidates. What makes miRNA detection complicated is
the short sequence length of the mature miRNA, its low abundance, and tracing a miRNA
to a specific cell or tissue type [32]. Commonly used detection methods include Northern
blot, RT-qPCR, and high-throughput methods, such as microarrays and NanoString. The
choice of detection method depends on the purpose of the experiment. For example, when
looking for miRNA signatures of disease, high-throughput methods are used to first define
the repertoire of miRNAs implicated in the disease state, and then a small subset of these
are validated by RT-qPCR [33–35].
2.3. Therapeutic Potential of miRNA
Various approaches support the leveraging of miRNA for therapeutic intervention,
depending on its role in a given disease. To silence a miRNA upregulated in disease,
antisense oligonucleotide “antagomirs”, or their chemically derived versions, such as
locked nucleic acids (LNA), as well as miRNA sponges, including circRNA, can be used.
Chemically modified oligonucleotides with higher affinity to the miRNA ‘seed region’ can
be used to block the miRNA’s effect and to also potentially interfere with the miRNA-
induced silencing complex [36]. miRNA sponges, which are longer nucleotides, can prevent
miRNA from binding to its mRNA targets [37]. Still, the utility of sponges as therapeutics
is limited given their potential off-target effects on exogenous nucleic acids. In diseases
characterized by miRNA deficiency (leading to the overexpression of an mRNA), miRNA
replacement therapy can be implemented [38] using mimics or “agomirs”. Combination
therapies have also shown promise. For instance, in oncology, miRNA mimics have
been used synergistically with anti-cancer treatments to render tumor cells that are more
susceptible to chemotherapy or radiotherapy [39].
miRNA mimics/agomirs and antagomirs need to be encapsulated to retain their
function. Lipid carriers (e.g., liposomes, lipid nanoparticles) and polymeric carriers
(e.g., cationic carriers such as polyethyleneimine) along with viral vectors, conjugates,
and exosomes can be explored for the delivery of miRNA therapeutics [38]. Decorating the
surface of lipid and polymeric nanoparticles with specific molecules can help to improve
targeting to desired cell and tissue types.
2.4. Limitations in Current Methodologies in miRNA Research
Given the ability of a single miRNA to regulate multiple genes, targeting miRNA has
the potential to simultaneously impact several disease processes, thus making miRNA
a more rewarding modality over siRNA, which is mRNA-specific. The downside of this,
however, is potential off-target effects, as well as undesired on-target effects, highlighting
the necessity of better understanding miRNA-regulated gene networks and critical nodes
therein. To advance miRNA-based therapeutics, the field needs to address challenges
in three main areas: [31,38]: (i) miRNA-regulated genes and gene networks; (ii) efficient
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miRNA delivery; (iii) animal models that recapitulate critical aspects of IBD and enable
testing the physiological role of miRNA and the impact of miRNA-targeted interventions.
miRNA and its putative networks remain incompletely understood. Until we have
a more comprehensive view of the pathways affected by miRNAs, there will be a high
burden to validate both on-target and off-target effects. Bioinformatics databases, such as
TargetScan [40] and miRBase [41] are available to predict putative miRNA targets to help
understand the affected networks. While these databases are a great resource for finding
potential mRNA targets, the experimental validation of the binding of miRNA(s) to target
mRNA(s) is a necessary validation step. Standardization in miRNA identification and
in tissue sourcing and sampling (e.g., fresh frozen tissues vs. formalin-fixed embedded
tissues) must also be clarified to ensure data reproducibility. Furthermore, since human
and animal tissue samples are often heterogeneous, determining the precise cellular origin
of miRNA is challenging.
While simpler model organisms, most notably nematodes, have been utilized to dis-
cover miRNAs and to identify their molecular functions, more complex and physiologically
relevant models are sought to study the role of miRNA in human disease. Since there
are higher risks of off-target effects with miRNA therapies, preclinical validation in ani-
mal model systems is imperative to progress miRNA as a therapeutic modality into the
clinic. While there is substantial research on miRNA mimics’ and antagomirs’ molecular
stability and affinity, which will aid in making miRNA therapy more efficacious [38], se-
lection of a suitable predictive animal model to study and test miRNA mechanisms, and
interventions is an equally important part of the preclinical process.
Given the pleiotropic nature of miRNAs, finding candidate miRNAs dysregulated in
a disease state could help develop miRNA-based therapies with the potential of correcting
complex networks of pathogenically disrupted proteins. This review article will explore
the mouse models used to study IBD, miRNAs implicated in these models and in IBD
patients, as well as potential nanoparticle miRNA therapeutics for IBD (Figure 1).
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Table 1. Mouse models of IBD and their similarities with human disease.
Group Subgroup Model Features Similarities with Human IBD References
Chemical agents Dextran Sodium Sulfate (DSS)Colitis Model.
• Administration: DSS in different concentrations is dissolved
in drinking water; depending upon the dosing conditions,
a mouse can develop acute or chronic colitis
• Pathophysiology: induction of indirect intestinal
inflammation due to epithelial injury limited to the gut
mucosa—disruption of the epithelial monolayer lining
causes the entry of gut microbiome and antigens followed
by immune cell activation in the underlying tissues.
• Disease manifestations: weight loss, bloody diarrhea, colon
shortening, crypt abscesses are formed; symptoms in the
large intestines are more pronounced than in the
small intestines
• Immune cells: lesions infiltrated by immune cells such as
neutrophils and macrophages near the damaged segment;
switches from Th1-Th17-mediated acute inflammation to
Th2-mediated in chronic colitis exhibiting Th1/Th2 cytokine
profile changes
• Cytokine and Chemokines: increased TNFα, IL-6, IL-17, and
Keratinocyte Chemoattractant (KC) in the acute state;
increase in IL-4, IL-10, and concomitant decrease in TNFα,
IL-6, IL-17; increase in myeloperoxidase activity.
• Chronic colitis induced by DSS resembles the
clinical course of human U—features such as
cryptitis and crypt abscesses due to transepithelial
neutrophil migration.
• miRNA commonly dysregulated: miR-223 (l) *,
miR-21 (l), miR-31 (↑), miR-146a (↑), miR-155 (↑),
miR-196a (↓), miR-142-5p (↑), miR-133b (l),
miR-135b (↓), miR-124 (↓).
[43–49]
Chemical agents Trinitrobenzenesulfonicacid (TNBS).
• Administration: TNBS (haptenating agent) is dissolved in
ethanol at different concentrations and delivered rectally;
depending upon the dosing conditions, a mouse can
develop acute or chronic colitis
• Pathophysiology: ethanol disrupts the epithelial barrier
enabling the interaction with haptenating TNBS, rendering
proteins immunogenic, causing acute cell-mediated
immune response by acute Th1 inflammation characterized
by infiltration of CD4+ T cells.
• Disease manifestations: dramatic weight loss, inconsistent
stool, occult or bloody diarrhea, reduction in colon length,
mucosal edema, distorted crypts, formation of abscesses,
diffused colonic inflammation
• Immune cells: T cell tolerance to the microbiota is disrupted,
exhibits heightened Th1-Th17 response
• Cytokines and Chemokines: increased IL-12, IL-23, and
IL-17; increased IFNγ.
• The NOD2 gene is involved in both TNBS-induced
colitis as well as human CD.
• The transmural nature of colitis and edema induced
by TNBS is similar to human CD.
• miRNA commonly dysregulated: miR-223 (↑),
miR-196a (↓), miR-10b (↓), miR-21 (↑), miR-133b (l),
miR-135b (↓), miR-142-3p (↑), miR-124 (↓).
[43,47,49–51]
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Table 1. Cont.
Group Subgroup Model Features Similarities with Human IBD References
Chemical agents Oxazolone
• Administration: intrarectal administration of oxazolone
dissolved in ethanol (haptenating agent)
• Pathophysiology: the haptenating agent induces
inflammation in the mucosal layers of mainly the distal
colon and is primarily characterized by Th2
cytokine response
• Disease manifestations: striking drop in body temperature,
colon tissue damage, loss of enterocytes and goblet cells,
edema, and dense immune cell infiltration
• Immune cells: higher proportion of CD3+ Ly49c+ and CD4+
natural killer T (NKT) cells, infiltration of neutrophils
and monocytes
• Cytokines and Chemokines: Th2-mediated responses, IL-4,
IL-13 (may be induced by IL-33 from damaged epithelial
cells or through IL-25), IL-9 (produced because of IL-13
stimulation and TGF-β).
• Resembles human UC in terms of intestinal
morphology and immunopathogenesis. [43,52,53]
Spontaneous colitis SAMP1/YitFcsJ mouse strain
• Derivation: selective and continuous brother-sister mating
of parental AKR/J mice that developed skin lesions and
ileitis formed the SAMP1/Yit colony, which upon constant
inbreeding led to SAMP1/YitFc sub strain.
• Pathophysiology: spontaneous ileitis without genetic,
chemical, or immunological manipulation; IFNγ production
at four weeks of age followed by ileitis at ten weeks of age;
host-microbial interactions amplify disease severity.
• Disease manifestations: inflammatory changes are
transmural and discontinuous, crypt elongation, villous
blunting, infiltration by polymorphonuclear and
mononuclear cells in the submucosa, cryptitis, crypt micro
abscess formation as the disease progresses. Thickening of
the bowel wall characterizes later stages of the disease.
Secretory cells outnumber the epithelial/absorptive cells as
the disease progresses.
• Immune cells: Th1 predominant in the early/inductive
phase of the disease and changes to a Th1/Th2 chronic
phase phenotype as severity progresses.
• Cytokines and Chemokines: chronic ileitis shows Th1 CD4+
cells that produce higher levels of TNFα and IFNγ and a
higher number of CD8 + α+T-cell receptor T cells.
• CD-like ileitis, pathogenesis resembles chronic
intestinal inflammation; useful for studying
pathways that precede the clinical phenotype.
• Common features to human CD include disease
location, the incidence of extra-intestinal
manifestations, perianal disease and fibrostenotic
strictures (hallmark features of human CD), and
response to conventional therapies.
[54,55]
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Table 1. Cont.
Group Subgroup Model Features Similarities with Human IBD References
Spontaneous colitis C3H/HeJBirLtJ mouse strain
• Derivation: selective breeding of the severely affected
C3H/HeJ mice with perianal ulcerations resulted in a
substrain C3H/HeJBir with a high incidence of perianal
ulceration and soft feces.
• Pathophysiology: mice develop a spontaneous and heritable
form of idiopathic IBD, developing defective mucosal
immune regulation allowing the activation of pathogenic T
cells against gut bacterial antigens
• Disease manifestations: perianal ulcers occur between
4–7 weeks and once healed, do not recur. Intestinal lesions
are present primarily in the cecum, and right colon,
characterized by acute and chronic inflammation, ulceration,
crypt abscesses, regenerative hyperplasia, and submucosal
scarring; less than 10% of cases develop occult blood, soft
feces, and large perianal ulcers.
• Immune cells: CD4+ T cells are quickly activated to produce
a Th1-type response, increased IgM B+ cells in Peyer’s
patches, increased intestinal S-IgA levels, higher level of
activation markers such as CD45RB and CD44 than those
from C3H/HeJ, elevated α4β7peripheral blood
lymphocytes and in colon intraepithelial lymphocytes when
compared to parental levels.
• Cytokines and Chemokines: CD4+ T cell in response to
bacterial antigens produce predominantly IL-2 and IFNγ.
• A valuable resource for genetic and immunological
studies of the disease.
• Mice develop an idiopathic chronic inflammatory
bowel illness that is heritable. Acute and chronic
inflammation, submucosal scarring, regenerative
hyperplasia, crypt abscesses, and ulcerations are
found in histopathology investigations of cecum
and proximal colon lesions.
[56,57]
Gene knockout (KO) B6.129P2-Il10
tm1Cgn/J
(IL-10 KO)
• Derivation: targeted deletion of IL-10 in mice leads to the
development of spontaneous inflammation; deletion of
IL-10 from Foxp3+ Treg cells also results in
spontaneous colitis.
• Pathophysiology: immune cell stimulation by gut bacteria is
critical for colitis development in this model; the aberrant
response of CD4+ Th1-like T cells.
• Disease manifestations: inflammatory infiltration by
lymphocytes, macrophages, and neutrophils.
• Immune cells: initial inflammation is pro-inflammatory Th1
T cell-driven, progressive increase in Th2 cytokines;
excessive inflammatory response may also be due to loss of
p100δ induction.
• Cytokines and Chemokines: after increasing Th1 T cell
response (IL-12, IL-17, and IFNγ), there is a reduction in its
production and increased Th2 cytokines IL-4 and IL-13.
• IL-10 locus polymorphism has been shown to
increase the risk for development of both UC
and CD.
• Colon histopathology shows similarities to human
IBD samples.
• miRNAs commonly dysregulated: miR-223 (↑),
miR-101 (↑), miR-155 (↑), miR-31 (↑),
miR-142-5p (↑), miR-21 (↑), miR-146a (↑).
[43,49,58,59]
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• Derivation: pancolitis and small bowel inflammation is
induced 5–8 weeks after adoptive transfer of naïve CD4 +
CD45RB (high) T cells from healthy wild type mice into
syngeneic mice (such as RAG KO) that lack T and B cells.
• Pathophysiology: disruption of T cell homeostasis; good
model for examining the early onset of disease
inflammation and perpetuation; naïve T cells are susceptible
to gut antigens, activating colitogenic T cells secreting
cytokines leading to small and large intestinal inflammation.
• Disease manifestations: transmural inflammation, dense
immune infiltration by neutrophils, crypt abscesses; varied
degree of weight loss, diarrhea, and loose stools depending
on the donor and recipient mouse strain.
• This model shows both colitis and small bowel
inflammation, which is similar to Crohn’s disease.
Disease manifestations, including epithelial cell
hyperplasia and cell erosion, transmural
inflammation, significant infiltration of leukocytes,
and crypt abscesses are similar to those seen in
human IBD.
• Delineates the immunological mechanisms in the
induction and regulation of chronic inflammation.
• miRNAs commonly dysregulated: miR-223(↑),
miR-146a (↑), miR-146b (↑), miR-142-5p (↑),
miR-21 (↑), miR-203 (↓).
[43,58,60,61]
* (↑), upregulated in both human and mouse; (↓), downregulated in both human and mouse; (l), inconsistent results between human and mouse.
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3.1. Humanized Mouse Models
In recent years, numerous therapeutic candidates have failed to succeed in clinical
trials at least in part because researchers have used experimental mouse models that do
not sufficiently recapitulate the human immune microenvironment. IBD is an autoimmune
disease involving complex interactions between multiple innate and adaptive immune cell
populations. Additionally, genetic factors, environmental triggers, and the gut microbiome
play significant roles in IBD. The differences between the mouse and human immune
systems—a sophisticated network of cells, tissues, and organs that has uniquely evolved to
defend against invading microorganisms—can thus fundamentally impact the fidelity of
a mouse model in mimicking disease pathogenesis. Thus, we may need to examine human
autoimmune diseases in the context of a functional human immune system in preclinical
animal models. The ideal model would allow for the testing of disease pathogenesis, longi-
tudinally enable detailed study of the human immune system during the disease course
and be economically feasible. For instance, severely immunodeficient mice homozygous
for targeted mutations in the IL-2 receptor γ-chain locus (IL2rg), particularly NOD-scid
IL2rgnull (NSG) mice, support heightened levels of engraftment with human hematopoietic
stem cells (HSC) and, notably, increased human T cell development. These mice lack host
T cells, B cells, and NK cells, facilitating more accurate in vivo study and the modeling
of human autoimmune diseases. The development of humanized mice has been recently
reviewed elsewhere [62–64].
Although functional human immune systems develop following human HSC engraft-
ment of NSG mice, human T cell function is not optimal. Human T cells in engrafted NSG
mice are educated on the mouse major histocompatibility complex (MHC). Hence, Shultz
and colleagues have developed new stocks of NSG mice that lack murine (MHC) class I and
II and transgenically express human MHC HLA class I and class II molecules to enhance
human T cell function following engraftment with HSC from human donors [65–68]. These
mice can be used to study and test regulatory T cell (Treg) therapies for IBD.
To develop a humanized mouse model of colitis, Goettel et al. [69] engrafted mice
selectively expressing an HLA class II allele with human CD4+ T cells and induced colitis
in reconstituted humanized mice using 2,4,6 Trinitrobenzenesulfonic acid (TNBS). TNBS
treatment (a single rectal enema containing 0.25 mg of TNBS in 50% ethanol) of NSG
mice selectively expressing human HLA-DR1 in the absence of mouse MHC class II
(NSG Abo DR1), engrafted with or without human CD4+ T cells from an HLA-DR1 donor,
resulted in significant weight loss only in NSG Abo DR1 mice engrafted with human
CD4+ T, but not in the non-reconstituted mice. Furthermore, using histopathological
analysis, the authors demonstrated extensive infiltration of CD4+ T cells into the colonic
lamina propria and crypt, as well as goblet cell loss with edema, fibrosis, and transmural
inflammation in NSG Abo DR1 engrafted with human CD4+ T cells, but not in non-
reconstituted NSG Abo DR1 mice. Lastly, using qPCR, the authors showed increased
transcript levels of TNF, IFNG, IL2, IL4, and IL17A. Together, these data suggest that in the
humanized TNBS-treated mice, human CD4+ T cells mediate disease pathology, and more
importantly, these mice enable the testing of human therapeutics targeting CD4+ T cells to
treat colitis.
Treg stimulation is a promising therapeutic method for improving immunological tol-
erance. In the humanized mouse model of colitis, Goettel et al. [69] used ITE [(2-(1′ H-indole-
3′-carbonyl)-thiazole-4-carboxylic acid methyl ester], a ligand of the cytosolic aryl hydro-
carbon receptor (AhR) transcription factor, to activate Tregs and suppress effector T cells.
The authors observed that ITE treatment increased the number of Tregs while decreasing
disease severity. Furthermore, in human T cells, ITE therapy boosted transcript levels of
multiple transcription factors associated with anti-inflammatory pathways. These data
further demonstrate the utility of the humanized TNBS-treated mice in evaluating the role
and targetability of T cell subsets.
Humanized mice have also been used in attempts to stratify patients for treatment
with specific therapies. Recently, Jodeleit et al. [70] engrafted NSG mice with peripheral
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blood mononuclear cells (PBMC) from 40 patients with ulcerative colitis (UC) following
sensitization of the mice with intrarectal application of 10% ethanol and tested the response
of these mice to Adalimumab therapy (Humira; FDA-approved for UC and CD). Analysis
of the immunological profile of the PBMC donor patients revealed two major subgroups
that reflected the dynamics of inflammation. The NSG recipient mice reconstituted with
the donor PBMCs and treated with Adalimumab mirrored the inflammatory phenotype of
the patients.
3.2. Genetic Diversity and IBD
Most mechanistic biomedical research in mice has been conducted using a single
inbred strain, C57BL/6. Studying disease in one strain of mice is equivalent to performing
research on one single person. Thus, it is not surprising when the results do not translate
across diverse patient populations. This limited genetic background may be one of the
contributing factors to the replication crisis [71]. IBD mice models can be divided into
four groups based on how the disease is induced in mice. During the past two decades,
genetic researchers have combined these different approaches to identify the genetic
contribution to disease. Studies have taken advantage of classic inbred mouse strains,
such as C3H/HeJ and C57BL/6J, to identify modifier loci, QTL, that affect the severity of
the IL-10 deficient mouse pathology [72,73]. A major finding of this work was identifying
a distal chromosome 3 locus related to induced colitis susceptibility and other QTL on Chr
1, 2, 4, 5, 8, 12, 17, and 18. Recent studies have utilized the diverse genetics of the Mus
musculus subspecies strain PWD/PhJ to identify regions on Chr 1 and 2 that contain loci
associated with high susceptibility to induced IBD [74]. The importance of genetic diversity
to phenotype variation has been discussed extensively (reviewed in [75,76])) and argues in
favor of a population-based approach to modeling human disease.
The recently derived mouse population, the diversity outbred (DO), and associated
collaborative cross (CC) strains allow for the interrogation of the genetic diversity of
45 million SNPs, similar to the diversity in the human population [77]. These strains of
mice are derived from an intercross of eight classical inbred strains to create a panel of
50–75 recombinant inbred lines (CC) having a genomic architecture derived from the
eight founder strains. These strains were outbred to produce the DO mice, which are
heterozygous and unique, with each mouse having a unique genetic makeup. Within
the panel of CC strains, there are phenotypes that, due to transgressive segregation, are
more diverse than any of the original eight founder strains. In producing the CC strains,
CC011/UncJ was identified as a strain that develops spontaneous colitis. Utilizing this
population to identify modifier loci, four QTL were mapped across the genome that explain
27.7% of the disease severity variation seen in this population [78]. Findings from these
modern genetically diverse populations demonstrate the ability to identify susceptibility
loci that impact our ability to model human disease.
3.3. Importance of Choosing the Right Mouse Model(s) to Study and Validate miRNA as
Therapeutic Targets
miRNA plays a significant role in determining immune cell fate decisions and reg-
ulating cell signaling pathways [79]. Conversely, changes in the cell signaling pathways
bring about differential expression of miRNAs associated with that pathway. When us-
ing IBD animal models, different aspects of the complex disease are recapitulated in each
model, and dysregulated pathways associated with these aspects will have a corresponding
miRNA or set of miRNAs differentially expressed, likely in a tissue-type specific manner.
Thus, to maximize translational relevance, it is essential to understand the consequences
of dysregulated miRNA expression as well as the cell signaling pathways linked with
this dysregulation.
Differential expression of miRNAs dysregulated in various mouse models of IBD high-
lights the importance of choosing the most appropriate mouse model for the given question
of interest. For instance, in a comprehensive study, Wu et al. [51] demonstrated that the
expression of miRNAs varies depending on the choice of the colitis mouse model. The
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authors found that several miRNAs, including miR-21, miR-223, miR-10b, and miR-142-3p,
show differential expression patterns between two commonly used mouse models of
colitis—dextran sodium sulfate (DSS)- and TNBS-induced colitis (Table 1). Whereas the
expressions of miR-21 and miR in the DSS model, they were upregulated in the TNBS-
model. Likewise, the express-223 downregulated ion pattern of miR-10b and miR-142-3p
were inconsistent between the DSS- and TNBS-models, indicating the inherent differences
between these two mouse models of colitis. Additionally, when the authors chose miR-21
for further in vivo analysis, as it is upregulated in the inflamed colonic mucosa of patients
with UC [34,35,80] and CD [34,80–83], they observed that the deletion of miR-21 in mice
significantly suppressed DSS-induced, but not TNBS-induced, inflammation and weight
loss. While this study clearly demonstrates the significance of miRNAs in the pathogenesis
of IBD, and that miRNAs are potential therapeutic targets in IBD, this also indicates the
care required in model selection, with ideally more than one mouse model being used for
preclinical validation of therapeutic targets.
4. MicroRNA as a Therapeutic Target in IBD
The epithelial barrier in the gut houses the largest volume of immune cells, as it
interfaces with the external environment [84]. The gut undergoes several insults through
pathogenic, chemical, or biological sources and, in healthy conditions, can overcome and
repair without causing chronic inflammation [85]. Several cells of both hematopoietic and
non-hematopoietic origin guard the gut to maintain homeostasis [84]. Aberrant activation
of the immune system due to various confounding factors can lead to chronic inflammation.
Indeed, several miRNAs are associated with the maintenance of mucosal immunity. Thus,
it is not surprising that the upregulation of pro-inflammatory cytokines that characterizes
chronic inflammation is associated with perturbation of upstream regulatory miRNA
networks. Clinical evidence implicates deregulated miRNA expression in serum samples
and intestinal tissue biopsies of UC and CD patients compared to healthy controls [33–
35,80–83,86]. In this section, we discuss the miRNAs known to be associated with common
pathophysiological pathways in IBD, specifically (a) epithelial barrier disruption and
(b) immune system dysregulation. We also discuss studies that have evaluated their
therapeutic prospects in preclinical models.
(a) Epithelial barrier disruption: The epithelial cells lining the gut interface with the
external environment and the gut microbiome on the luminal side. Integrity between
epithelial cells allows passive transport of nutrients from the lumen while restricting
pathogen entry. Tight junctions (TJ), adherens junctions (AJ), gap junctions, and desmo-
somes connect adjacent cells, regulate the transport of molecules from the luminal side,
and participate in various intracellular signaling pathways [87–89]. They form the apical
junctional complex (AJC). Selective paracellular permeability based on charge and size is
controlled via TJs [90]. The TJ is made up of transmembrane proteins (occludin, tricellulin,
claudins, and junctional adhesion molecules) and peripheral membrane proteins (Zona
occludens (ZO)-1,2,3 and cingulin) [91]. AJs play a role in cell–cell adhesion, and tissue
development and homeostasis [89]. Gap junctions aid in nutrient transfer from one cell to
another [89]. Desmosomes impart structural support to the cells in the tissue [89]. Mucosal
inflammation brings about several changes in these stable intercellular junctions, thereby
perpetuating chronic inflammation in diseases such as IBD. These junctional proteins have
hence become lucrative targets to alleviate IBD.
Another class of peptides that play a role in maintaining homeostasis is the Trefoil
Family (TFF), which is secreted by mucus-producing cells and goblet cells in the lumen to
maintain homeostasis [92]. TFF3 is a type of TFF most commonly found in the colon, has
anti-apoptotic properties [93] and has been shown to induce cell migration in vitro [94].
Several miRNAs contribute to epithelial integrity and homeostasis by regulating the ex-
pression of proteins involved in the maintenance of epithelial barrier integrity. Below, we
discuss the therapeutic potential of targeting these miRNAs.
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(a.1) miRNA therapeutic intervention in epithelial barrier disruption (Table 2): OCLN
encodes occludin, a tight junction protein responsible for regulating paracellular transport.
One study analyzed colonic biopsies for occludin mRNA expression from 54 individuals
divided into three groups of active UC (n = 20), remission UC (n = 16), and healthy controls
(n = 18) [95]. They found that occludin expression in the remission UC group was signifi-
cantly lower than in the control group, and in active patients was higher [95]. According to
TargetScan, several miRNAs, including miR-200b-3p, miR-200c-3p, miR-122a, and miR-429,
target OCLN mRNA. For instance, in Caco-2 cells, TNFα, a pro-inflammatory cytokine
upregulated in IBD patients, induces the degradation of occludin mRNA through the rapid
expression of miR-122a [96]. Treatment with modified antisense miR-122a (dose: 25 nM,
complexed with Lipofectamine 2000) reversed this effect when tested in the intestinal
perfusion model [97]. There was an increase in occludin mRNA levels, suggesting that
antisense miR-122a has the potential to be explored for barrier maintenance [96]. Another
pro-inflammatory cytokine that affects occludin expression is IL-1β. IL-1β has been impli-
cated in modulating intestinal permeability and in IBD pathogenesis [98–100]. A recent
study by Rawat et al. revealed that the intraperitoneal administration of IL-1β in mice
caused a marked decrease in occludin mRNA, but an increase in miR-200c-3p levels [101].
To establish the link between occludin mRNA and miR-200c-3p, the authors inhibited
miR-200c-3p expression in Caco-2 cells stimulated with IL-1β and observed increased
occludin mRNA levels [101]. Additionally, in the DDS colitis model (3%), an oral gavage
of antagomiR-200c-3p (dose: 800 mg/day, starting two days before DSS treatment and
continued for seven days of DSS course), prevented the loss of occludin expression and
maintained the barrier function [101].
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Table 2. miRNA tested in relevant preclinical IBD models for improvement of barrier function and reduction in inflammation.
Outcome miRNA Model Treatment Dose and Regimen Ref
Occludin upregulation
miR-122a Intestinal Perfusion Model Anti-miR-122a Dose: 25 nM, complexedwith Lipofectamine. [97]
miR-200c-3p 3% DSS Antagomir-200c-3p
Dose: 800 mg/day, starting two days
before DSS treatment and continued
for seven days of DSS course;
oral gavage.
[101]
miR-21 miR-21 KO mice, 3.5% DSS




Claudin CLDN1 upregulation miR-29a and b miR-29 KO mice, TNBS Mice tolerated TNBS inducedbarrier disruption N/A [103]
Claudin CLDN8 upregulation miR-223 TNBS Antagomir-223
Dose: 7.5 mg/kg, prepared as
3 mg/mL in PBS, dosed for




upregulation miR-146b-5p TNBS antagomir-146b-5p Not specified [105]
Trefoil factor family 3
(TFF3) upregulation miR-7 TNBS Antagomir-7
Dose: 100 nmol/kg, tail vein injection,
2 h after TNBS perfusion. [106]
Bcl-2 upregulation miR-16 3% DSS Anti-miR-16
Dose: 5 mg/kg IP administration,




WNT and Hippo signaling miR-31 3.5% DSS
oxidized konjac glucomannan
(OKGM)-PS-miR-31 microspheres
Dose: 3.15 µg, enema.
Preventative mode: once per day for
7 d, 2 d gap, 5 d DSS treatment.
Therapeutic mode: 5 d DSS treatment,
once per day for 7 d; microsphere
enema.
[108]
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Table 2. Cont.
Outcome miRNA Model Treatment Dose and Regimen Ref
NF-kB pathway dampening
miR-146a 3% DSS miR-146a mimics Dose: 5 mg/kg, IP administration. [109]
miR-214 DSS AntagomiR-214
Dose: 12 mg/kg, 2.5 mg/mL diluted in




IL10RA activation miR-142-5p CD4 + CD45RO + hitransfer AntagomiR-142-5p 5 mg/kg, IP, 5 consecutive daysstarting at 5–10% weight loss; IP [58]
NLRP3 inhibition miR-223 3% DSS miR-223 mimic
Dose: 50 µg, nanoparticle emulsion-
DOPC, squalene oil, PS-20 and an
antioxidant, on days 1 and 3 after DSS.
[111]
Macrophage polarization
miR-146b IL-10 KO miR-146b mimics Dose: 10 mg/kg, twice a week;IP administration [112]
miR-146b 3% DSS miR-146b mimic
Dose: 20 µg/kg, encapsulated in
mannose modified trimethyl chitosan
nanoparticles; oral administration
[113]
miR-98-5p 4% DSS Antagomir-98-5p Caudal vein administration [114]






miR-155 miR-155 KO, 1% DSS Lower levels of Th17 upon DSSinduced colitis observed N/A [116]
miR-155 3% DSS AntagomiR-155
Dose: 80 mg/kg, from the 5th day of




Dose: 5 mg/kg, 12 h after TNBS
treatment, complexed with PEI;
intracolonic administration
[118]
miR-31 IL10 KO Antimir-31
Dose: 5 mg/kg, weekly for IL10 KO
mice, complexed with PEI; intracolonic
administration
[118]
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Table 2. Cont.
Outcome miRNA Model Treatment Dose and Regimen Ref
miR-301a TNBS Anti-miR-301a
Dose: 3 optical density, intracolonic
administration daily, starting at the
day of TNBS induction till 5 d.
[119]
miR-219a-5p TNBS Pre-miR-219a-5p
Dose: 5 mg/kg, complexed with PEI,




SBP1 downregulation miR-122 TNBS Pre-miR-122
Dose: 5 mg/kg, 12 h after
TNBS treatment [121]
RhoA reduction miR-31-3p 2% DSS AgomiR-31-3p




DSS: dextran sodium sulfate; TNBS: 2,4,6-trinitrobenzene sulfonic acid; KO: knock out; IP: intraperitoneal; PEI: polyethyleneimine, SBP1: selenium binding protein 1; DOPC: 1,2-dioleoyl-sn-glycero-3-
phosphocholine; PS-20: polysorbate-20.
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In UC patients’ colonic biopsies, lower levels of Occludin and ZO-1 are linked to
significantly greater levels of miR-21. Yang et al. transfected Caco-2 cells with miR-21
mimics to determine the underlying molecular mechanisms and found that miR-21 mimics
resulted in not only reduced levels of Occludin and ZO-1, but also increased permeability,
as evidenced by a decrease in the transepithelial electrical resistance (TEER) across the
Caco-2 monolayer [123]. Shi et al. reported that miR-21 KO mice are much less sensitive
to DSS-induced colitis (3.5%) than control mice, which they attribute to miR-21-mediated
intestinal permeability modulation [102].
Claudins are a family of 27 transmembrane proteins that enable epithelial cell–cell
adhesion, establishing paracellular barrier function, among other functions [124]. One such
protein, CLDN1, was shown to be upregulated in Mir-29−/− mice, which show loss of
miR29a and miR29b activity [103]. These mice were able to tolerate small intestine and
colon barrier disruption better than wild-type mice when treated with TNBS to induce coli-
tis [103]. Target validation studies revealed that miR-29a and b regulated NFKB Repressing
Factor (NKRF) mRNA, another barrier protection gene, in addition to CLDN1 [103]. These
gene knockout studies suggest that the inhibition of miR-29a and miR-29b is a potential
therapeutic strategy to restore intestinal permeability in IBD [103]. Another study eluci-
dated that miR-233 mediates crosstalk between the IL-23 pathway and the intestinal barrier
through the regulation of Claudin 8 (CLDN8) expression. IL-23 plays a key role in the
pathogenesis of IBD [125–127]. Wang et al. [104] tested the hypothesis that IL-23 suppresses
CLDN8 expression through miR-223 to mediate IBD, by inhibiting miR-233 expression
via the intraperitoneal administration of antagomir-223 (dose: 7.5 mg/kg, prepared as
3 mg/mL in PBS, dosed for three successive days 24 h after TNBS administration) in
the TNBS-colitis model. The authors observed that the inhibition of miR-223 restored
CLDN8 expression, restored barrier function, and alleviated inflammation, resulting from
TNBS-induced colitis [104].
Two AJC proteins, NUMB and CLDN11, help maintain intestinal barrier integrity.
The AJC can be disrupted by MALAT1 (Metastasis Associated Lung Adenocarcinoma
Transcript 1), a lncRNA that is found to be downregulated in the colonic intestinal mucosa
of CD patients [105]. A recent study revealed that MALAT1 affects intestinal permeability
by sequestering miR-146b-5p, which targets the 3′ UTR of NUMB and CLDN11 mRNA
and thus suppresses their expression [105]. In a TNBS model of colitis, treatment with
antagomir-146b-5p, but not a negative antagomir control, restored barrier integrity by
enhancing the protein levels of NUMB and CLDN11 [105].
Cingulin, expressed in the cytoplasm, interacts with many components of AJs and TJs.
Notably, cingulin expression is significantly downregulated in UC patients [128]. A study
explored the cingulin-miRNA interaction and found that miR-24 is overexpressed in the
crypts of colonic biopsies and the serum of UC patients compared to healthy controls [128].
Further experiments in Caco2 cells to elucidate the association between cingulin and
miR-24 in disruption of intestinal barrier integrity revealed that miR-24 targets cingulin
mRNA to cause barrier disruption. Thus, it might be beneficial to explore miR-24 inhibitors
to enhance cingulin expression and restore barrier function in UC patients.
Hypoxia has also been studied in the context of IBD, and several studies showed that
hypoxia inducible factor 1 subunit alpha (HIF-1α) inhibitors improve intestinal barrier
function when administered orally [129] or intraperitoneally [130]. miR-135a was found
to be suppressed in both UC and CD patients [86]. Lou et al. [131] showed that the DSS
model (4% DSS) recapitulates human colitis and results in the significant downregulation
of miR-135a. Furthermore, the authors showed that HIF-1α is a target of miR-135a, and
that the downregulation of miR-135a enhances HIF-1α expression to promote apoptosis
and inflammation. Consistently, the overexpression of miR-135a in colonic epithelial cells
prevented apoptosis and inflammation by inhibiting the expression of apoptotic factor
Bax and enhancing the expression of anti-apoptotic factor Bcl-2 via HIF-1α [131]. Another
study found a negative correlation between miR-16 and Bcl-2 expression in Caco-2 cells
and in the colonic mucosa of DSS-treated mice [107]. Further investigation in 3% DSS
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induced colitis mice (two weeks) with the intraperitoneal administration of anti-miR-16
(dose: 5 mg/kg, twice per week) alleviated colitis and reduced proinflammatory cytokines
in comparison to PBS-treated DSS controls [107].
Along with TJs, which help maintain the integrity of the intestinal epithelial barrier,
TFFs help maintain, regenerate and restore barrier function in response to acute injury and
chronic inflammation [92]. TFF3, a type of TFF, was shown to be negatively regulated by
miR-7 in human colonic epithelial cells LS174T [132,133]. Furthermore, miR-7-5p levels
were upregulated in the inflamed lesions of pediatric patients compared to uninflamed
tissue [133] and TNBS-treated mice [106]. Subsequently, the team explored the effects
of the inhibition of miR-7 in a preclinical colitis model [106]. Tail vein administration of
100 nmol/kg of antagomir-7 2 h after TNBS administration and subsequent assessment
of the intestinal tissue harvest seven days after treatment revealed improved histological
colitis scores, higher TFF3 production, and a reduction in colitis-induced damage [106].
miRNA targets that are relevant to epithelial permeability in the context of other
diseases could potentially also be applied to IBD. For example, miR-155 is upregulated
in the intestinal epithelial tissues in severe acute pancreatitis animal models, resulting in
the upregulation of TNF-α in the serum [134]. This, in turn, causes the downregulation
of various AJC proteins such as ZO-1 and E-cadherin, disrupting the intestinal epithelial
barrier [134]. Similarly, in an animal model of intestinal ischemia-reperfusion, miR-21
was upregulated, which correlated with the upregulation of several pro-inflammatory
cytokines, and thereby intestinal barrier disruption [135]. Moreover, several miRNAs also
play a role in central nervous system disorders due to their role in maintaining the integrity
of the blood–brain barrier (reviewed in [136]), and further research is needed to ascertain
their possible relevance in IBD.
(b) Immune system dysregulation in IBD: The large volume of immune cells in the
gastrointestinal tract ensures the safekeeping of internal organs. These cells constantly
interact with ingested materials while maintaining homeostasis with the gut microbiota [84].
Although these are foreign, the host immune system under healthy conditions is not
overstimulated in the presence of microbiota, thus maintaining a delicate immune balance
in the gut. The first line of defense is the innate immune system, which, through NOD-like
receptors (NLRs) and pattern recognition receptors (PRRs) sense foreign microorganisms
and initiate an immune response to dispose of the invaders. PRRs are present on immune
cells, such as macrophages and dendritic cells (DCs), epithelial cells, and myofibroblasts,
which together maintain gut immune homeostasis [137]. The endpoint effects of PRR
stimulation are generally the release of pro-inflammatory cytokines. Macrophages and DCs
also act as antigen-presenting cells (APCs), linking innate and adaptive immune systems.
The adaptive immune system is the second line of defense and is more nuanced than the
innate immune system. Information from APCs helps prime the adaptive immune cells to
orchestrate the immune response via T cells and B cells.
In IBD, innate sensing dysregulation causes an aberrant increase in the levels of pro-
inflammatory cytokines, which leads to chronic inflammation if not checked and resolved.
In addition, during chronic inflammation, the dysregulation of the adaptive immune
system sustains the levels of pro-inflammatory cytokines. Inflamed tissues in IBD patients
are infiltrated by activated immune cells, which initiate a cascade that ultimately leads
to the overexpression of pro-inflammatory cytokines, such as TNFα, IL-6, IL1B, IFN-Y,
IL-17A, IL-12, IL-23, IL-18, and the downregulation of anti-inflammatory cytokines, such
as TGF-B, IL-10, IL-25, IL-33, IL-37 [138]. Below, we summarize studies indicating how
targeting miRNAs alleviates an overactive immune system.
(b.1) miRNA therapeutic intervention in immune system dysregulation (Table 2):
NFκB signaling transcribes pro-inflammatory cytokines and plays a crucial role in innate
and adaptive immune responses [139]. Acting as a fine-tuner of innate signaling, miR-146a
targets Tumor necrosis factor receptor-associated factor 6 (TRAF6) and Interleukin 1 Re-
ceptor Associated Kinase 1 (IRAK1) that are both upstream proteins in the NFκB signaling
pathway, keeping the production of pro-inflammatory cytokines in check [140]. A colonic
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biopsy study has shown that miR-146a is significantly elevated in UC patients compared
to CD patients [64]. Another study showed elevated miR-146 expression in both UC and
CD pediatric patients, compared to intact mucosa [141]. The elevation could be due to
TLR4 activation, which induces the transcription of miR-146a via the NFκB pathway [140].
Notably, miR-146a is not restricted to myeloid cells but is also expressed by intestinal
epithelial cells [109,142]. miR-146a KO mice were more susceptible to endotoxin challenge
and developed spontaneous autoimmune disorders upon aging [143]. A recent study
also elucidated that, by targeting TRAF6 in intestinal epithelial cells (IECs) and Receptor
Interacting Serine/Threonine Kinase 2 (RIPK2) within the myeloid cells, miR-146a can
keep IL-17 signaling in check, repressing inflammation further and suppressing tumor
growth [109]. The same group further demonstrated that treatment, with miR-146a mimics
administered intraperitoneally (dosed at 5 mg/kg) in the DSS (3%) colitis model, im-
proved disease outcome [109]. Along with the negative regulation of TLR/IL-1R signaling,
miR-146a controls Treg cell conversion into IFN-γ-producing Th1 cells mediated via the
signal transducer and activator of transcription 1 (STAT1) [144] and, thus, controls hyper-
responsiveness in T cells [145], further underscoring its therapeutic utility in preventing
excessive inflammation.
A study explored the inhibition of miRNAs in human colonocytes (NCM460) and its
effect on NFκB activation via stimulation by IL-6. From a list of 348 miRNA inhibitors
explored, the inhibitor of miR-214 suppressed phospho-NFκB most efficiently (>90%) [110].
The group further found that miR-214 in colonic tissues of UC patients was expressed
8-fold higher, compared to control subjects [110]. Mechanistically, IL-6 stimulation induces
the upregulation of STAT3-mediated transcription of miR-214, leading to reduction in the
levels of phosphatase and tensin homolog (PTEN) and PDZ and LIM domain 2 (PDLIM2),
ultimately increasing the phosphorylation of AKT and activation of NFκB. The higher
expression of miR-214 is observed in long-term UC patients (>10 years) compared to short-
term UC patients (0–10 years). Furthermore, in mice, DSS-induced colitis significantly
upregulates miR-214 expression. Utilizing the DSS model of colitis, the authors examined
whether intracolonically administered miR-214 antagomirs (dose: 12 mg/kg, 2.5 mg/mL
diluted in PBS, 4 doses, every 2 days after DSS treatment regime) reduce disease severity.
Expectedly, miR-214 antagomirs significantly reduced the disease activity index in DSS-
treated mice [110].
Tian et al. recently studied the effect of inflammation on miR-31 and found that the
inflamed mucosa of UC and CD patients had elevated miRNA levels, while the levels
were reduced to uninflamed levels in patients under remission [108]. NFκB and STAT3
pathway activation upregulated miR-31 in human colon epithelial cell line LOVO and
primary mouse colon organoids. Furthermore, DSS- and TNBS-induced colitis in miR-31
KO mice developed more severe colitis than in WT mice. The group also found that the
overexpression of miR-31 improved colitis in TNBS treated mice. Further investigation
revealed miR-31′s role in suppressing IL6st, IL17r, and IL17ra genes within the colonic
epithelial cells, all implicated in IBD. Further target evaluation also revealed the role of
miR-31 in promoting epithelial regeneration by regulating the WNT and Hippo signaling
pathways. Given the ability to target multiple genes at once, miR-31 mimics were utilized
as a therapy by encapsulating the mimics in peptide-based oxidized konjac glucomannan
(OKGM)-PS microspheres (3.15 µg) administered via enema. The therapeutic intervention
reduced 3.5% DSS-induced colitis severity and recovery in WT mice, both in preventative
and therapeutic dosing regimens, respectively, bolstering the utility of both miR-31 mimics
and the delivery system [108].
The NLRP3 inflammasome is assembled in response to the innate sensing of micro-
biota and damage-associated molecular patterns (DAMPs), and the disruption of this
process can lead to dysbiosis and pyroptosis within myeloid cells, both of which even-
tually cascade into chronic inflammation, as in IBD [146]. miR-223 regulates the NLRP3
inflammasome [147] and plays a critical role in myeloid cell development, negatively
regulating proliferation, cell fate, and activation [148]. Dysregulated miR-223 expression is
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observed in IBD, chronic obstructive pulmonary disease [149], rheumatoid arthritis [150],
and type 2 diabetes [151,152]. In IBD, miR-223 is upregulated in the colonic mucosa of pa-
tients with UC [80,83] and CD [33,80–83], as well as in animal models of colitis [48,49,51,58].
Neudecker et al. elucidated that the miR-223 controls enteric inflammation by targeting
the NLRP3 inflammasome [111]. In mice, DSS upregulates miR-223 levels in the colon as
early as day two after treatment. To study the source of miR-223 induction, neutrophils
were deleted in B6/J mice via antibodies, followed by DSS treatment. Neutrophil de-
pletion significantly reduced miR-223 expression, indicating that infiltrating neutrophils
could be the source of miR-223 [111]. Furthermore, since miR-223 targets the 3′ UTR
of NLRP3, studies using miR-223 KO mice [148] showed higher NLRP3 protein levels
in the colon of DSS-treated mice when compared with untreated controls. Furthermore,
blocking NLRP3 significantly improved the disease pathology in DSS-treated miR-223
KO mice [111], indicating a potential therapeutic strategy using miR-223 mimics to tar-
get the NLRP3 inflammasome. To this end, the authors retro-orbitally administrated a
nanoparticle emulsion encapsulating miR-223 mimics (dose: 50 µg, complexed with NLE:
DOPC, squalene oil, PS-20, and an antioxidant) on days 1 and 3 after 3% DSS treatment in
wild-type mice. miR-223 significantly mimics suppressed NLRP3 mRNA and attenuated
the transcript levels of several pro-inflammatory cytokines, including IL-1β, IL-6, and
TNF [111].
Macrophage phenotypes exist in a spectrum between M1, representing a pro-inflammatory-
skewed phenotype, and M2, representing an anti-inflammatory-skewed phenotype. The
IRF5 transcription factor is known to cause M1 differentiation [153,154]. It is well known
that IL-10 KO mice spontaneously develop colitis [59,155]. Investigating this model for
macrophage polarization revealed abundance in the M1 phenotype [112]. Furthermore,
miR-146b was found to target IRF5 [112]. To assess the therapeutic potential of miR-146b,
IL-10 KO mice given mimics intraperitoneally (IP) (dose: 10 mg/kg, twice a week) showed
improved disease outcome including weight and tissue morphology along with signifi-
cantly lower IL-12p40- and MHCII-expressing macrophages when compared to scrambled
control [112]. miR-146b was further explored as a therapeutic entity by Deng et al. [113].
Their study found the upregulation of miR-146b in mucosal samples three days after 3%
DSS withdrawal and detected an abundance in lamina propria cells compared to epithelial
cells. Simultaneously, M2-associated cytokines also increased three days after 3% DSS with-
drawal [113]. Next, the team loaded miR-146b mimics into mannose-modified trimethyl
chitosan (MTC) nanoparticles that could target the mannose receptor on macrophages
and delivered them orally (dose: 20 µg/kg) in 3% DSS-treated mice. They observed
that, while the colon tissue morphology was damaged to the same extent in both MTC-
non-coding and MTC-miR-146b groups, the latter recovered faster in both body weight
and epithelial structure three days after DSS withdrawal, along with an increase in M2
phenotype signature proteins in the colonic mucosa [113]. While this established MTC-
miR-146b’s effect on macrophage polarization, the group further investigated mucosal
regeneration in an in vitro system of miR-146b-treated bone marrow-derived M1 cells atop
a scratched “wounded” fetal human colon cell monolayer [113]. The results showed a
closure of the wound, mediated by STAT3-dependent IL-10 production from miR-146b-
mimic treated macrophages, demonstrating the utility of miR-146b as an anti-inflammatory
target as well as bringing about mucosal regeneration [113]. miR-98-5p has also been
implicated in macrophage polarization by targeting Trib1, which controls macrophage
polarization [114]. DSS (4%)-treated mice (8 weeks old) treated with antagomir-98-5p
administered through the caudal vein showed downregulation of M1-phenotype-related
cytokines and the upregulation of M2-phenotype-related cytokines resulting in an im-
proved disease activity index [114]. Another strategy of miR-98-5p inhibition was explored
using lncMEG3, which targets and inhibits miR-98-5p expression [115]. Upon adminis-
tration of pcDNA3.1-MEG3 complexed with Lipofectamine 2000 to TNBS (150 mg/kg of
TNBS in 50% ethanol, 50% v/v)-induced Sprague Dawley rats, the MEG3-expressing rats
showed reduced expression of miR-98-5p, ROS, TNFα, IL-1β along with higher expres-
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sion of IL-10 and improved disease activity index [115]. Another miRNA that regulates
macrophage polarization is miR-125b, which is enriched in macrophages over lymphoid
cells [156]. RAW264.7 macrophages treated with miR-125b were overactivated when stim-
ulated with IFN-γ due to increased expression of IFN-γR on their surface [156]. These
cells also displayed higher CD80 expression on their surface, indicating an inflammatory
phenotype [156]. Anti-miR-125b-treated cells were less responsive to IFN-γ treatment and
exhibited reduced levels of CD80 and reduced T cell activation, suggesting a treatment
strategy for IBD [156,157].
STAT3 plays a differential role depending on the immune system milieu in which
it is activated. In colitis, while STAT3 activation leads to pathogenic T cell survival in
the adaptive compartment, it contributes to the suppression of inflammation in colonic
epithelial cells and macrophages (reviewed in [158]). STAT3 was shown to be upregulated
in the colon of pediatric UC patients. Subsequent investigation revealed that miR-124
targets STAT3 in NCM460 colonic epithelial cells [159], RAW264.7 macrophages, and THP1
macrophages [160]. Consistent with this, STAT3 upregulation correlates with miR-124
downregulation in the colonic biopsies of pediatric UC patients [159] and in the intestinal
macrophages of pediatric intestinal failure (IF) patients [160]. A similar correlation between
miR-124 and STAT3 expression levels was observed in DSS [159] and IL-10 KO [159] mouse
models of colitis. Moreover, the transfection of miR-124 mimics inhibited the release of
pro-inflammatory cytokines upon stimulation of RAW264.7 macrophages [160,161] and
THP1 macrophages [160] with bacterial endotoxin lipopolysaccharide (LPS) STAT3 inhibi-
tion [160]. Recently, in a randomized controlled Phase 2a trial, Vermeire et al. evaluated
the efficacy of orally administered small molecule ABX464 or placebo for eight weeks
in 32 patients with moderate to severe UC [162]. The proposed mechanism of action for
ABX464 involves the splicing of lncRNA 599-205 that releases miR-124 in macrophages [163]
to promote anti-inflammation [164]. While 20 patients received ABX464, 9 patients received
placebo. Overall, ABX464 was well tolerated with no severe adverse effects, strongly
recommending a Phase 2b trial to start detecting an efficacy signal.
On the contrary, the downregulation of STAT3 expression was associated with an
increase in the transcript levels of pro-inflammatory cytokines. DSS treatment of Caco-2
and HT-29 cells significantly downregulated STAT3 and miR-135a expression, while there
was a simultaneous increase in pro-inflammatory cytokine expression [165]. miR-135a
showed anti-inflammatory properties, as treatment with mimics activated STAT3 signal-
ing and lowered pro-inflammatory cytokines [165]. Together, these data suggest that
the pro-inflammatory or anti-inflammatory effect of STAT3 activation depends on the
cellular context.
miRNAs play a role in regulating the plasticity of T cells [166]. miR-10a was upreg-
ulated in naturally occurring Treg cells and preserved the Treg phenotype by targeting
(B Cell Lymphoma 6) Bcl-6 [166]. miR-10a in IEC lamina propria dendritic cells is con-
trolled by microbiota as seen by differential miR-10a expression in the colon of normally
housed mice vs. germ-free housed mice, aiding to maintain intestinal homeostasis [167].
In a clinical context, miR-10a was downregulated in inflamed mucosal tissues vs. normal
tissues of UC and CD patients [168]. These authors further studied the role of miR-10a
in these patients by lentiviral pre-miR-10a transfection of peripheral blood CD4+ T cells
isolated from UC and CD patients, and healthy controls, and observed a reduction in
cytokines associated with Th1 and Th17, indicating miR-10a’s role in regulating T cell
differentiation [168]. Additionally, miR-10a targeted multiple cytokines implicated in IBD,
such as IL-12/IL-23p40, NOD2, and NFκB pathways [167,168]. These investigations reveal
the potential of miR-10a mimics in restoring intestinal homeostasis by influencing host
microbiota responses.
miR-155 inhibition in LPS-stimulated RAW 264.7 cells leads to the downregulation
of inflammatory cytokines by downregulating pNFκB and NLRP3-related proteins [169].
Along with its role in innate immunity, it also plays a role in adaptive immunity by
contributing to the differentiation of CD4+ T cells into various subsets of helper T cells
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(Th1, Th2, Th17) and Treg cells [170]. Th17 and Treg cells maintain a balance to ensure
homeostasis, and dysregulation increases IBD susceptibility [171]. Singh et al. found that
8–12-week-old miR-155 KO mice have lower levels of Th17 cells in the mesenteric lymph
nodes in response to chronic DSS-induced colitis (1% DSS administered for seven days
followed by seven days of water, treatment regime repeated for three cycles) along with
reduced pro-inflammatory cytokines [116]. Zhu et al. tested the therapeutic potential of
miR-155 antagomirs in the context of maintaining the balance between Th17 and Treg
cells [117]; in C57BL6/J mice (6–8 weeks-old) treated with 3% DSS, IP administration
of miR-155 antagomirs (dose: 80 mg/kg, from the 5th day of the DSS cycle, for three
consecutive days) significantly improved the disease activity index compared to untreated
controls [117]. Furthermore, the authors found that the inhibition of miR-155 in the
antagomir-treated group showed a reduced number of Th17 cells and a decline in IL-17A
and IL-6 levels but an increase in Treg cells, IL-10, TGF-B1, in the mesenteric lymph nodes,
indicating the maintenance of Th17/Treg cell balance as a strategy to alleviate colitis [117].
IL-25 is downregulated in inflamed mucosa of IBD patients and participates in CD4+ T
cell differentiation into Th1/Th17 via IL-10 [172]. Shi et al. showed an inverse relationship
between IL-25 and miR-31 expression in primary mouse colonic macrophages and epithelial
cells, the colon of CD patients, and mouse colitis models (TNBS and IL-10 KO mice) and
further confirmed via target validation studies that miR-31 targets the 3′ UTR of IL-25
mRNA [118]. The team explored the therapeutic potential of miR-31 antagomirs in TNBS
and IL10 KO mice by intracolonically administering antimiR-31 (dose: 5 mg/kg) complexed
with polyethyleneimine (PEI, 25kDa) 12 h after 3 mg TNBS in 100 µL 50% ethanol injection
in female BALB/c mice (6–8 week), and weekly administration from ages 12–20 weeks in
IL-10 KO mice [118]. Compared to untreated controls, treatment with antimiR-31 in both
colitis models improved intestinal histology and weight recovery, and showed a marked
decrease in IFN-γ+Th1 and IL-17A+ Th17 cell populations, indicating a role in alleviating
inflammation via the regulation of Th1/Th17 response [118].
Another miRNA implicated in Th17 differentiation is miR-301a [119]. Inflamed mu-
cosa and peripheral blood-derived monocyte cells of UC and CD patients showed elevated
levels of miR-301a [119]. Furthermore, CD4+ T-cells isolated from the peripheral blood of
IBD patients when transduced with miR-301a lentivirus (LV-miR-301a) showed increased
transcript levels of IL17a, RORC, and TNFα. In contrast, treatment with LV-anti-miR-301a
showed significantly lower levels of these mRNAs compared to controls. Mechanistically,
miR-301a targets SNIP1, which is implicated in the suppression of Th17 differentiation.
Then, the team tested the effects of miR-301a inhibition by the intracolonic administration
of miR-301a in TNBS treated mice, which improved the pathological scores, lowered levels
of IL17A, RORγt, TNFα, and increased the expression of Foxp3 in the colonic mucosa when
compared to the anti-miR control treatment [119].
A recent study explored the role of miR-219a-5p on Th1/Th17 differentiation in
IBD [120]. The group studied the inflamed mucosa of CD and UC patients and found
the levels of miR-219a-5p to be lower than the normal mucosa of the same IBD patients.
Furthermore, isolated peripheral blood (PB) CD4+ T-cells from IBD patients showed lower
miRNA levels than PB CD4+ T-cells from healthy donors. Subsequent pro-inflammatory
stimulation of PB CD4+ T-cells from healthy donors also revealed low miRNA levels. Addi-
tionally, when PB CD4+ T cells from IBD patients were transduced with lentivirus-encoding
miR-219a-5p, it reduced IFN-γ+ and IL17A+ CD4+ T cells in addition to pro-inflammatory
cytokines. Studying the effects on mice, TNBS-induced colitis mice showed reduced lev-
els of miR-219a-5p in the colorectal tissues compared to healthy controls. Therapeutic
intervention by intraperitoneal administration of pre-miR-219a-5p (dose: 5 mg/kg) com-
plexed with PEI for four consecutive days, starting 12 h after TNBS injection, improved
the pathological scores compared to control by suppressing Th1/Th17 mediated immune
responses [120].
In the CD4 + CD45RO+hi transfer colitis model, authors investigated the effects of
antagomiR-142-5p (5 mg/kg) treatment (starting at 5% weight loss for 5 days) by profiling
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the gene expression in the colons of these mice [58]. Transcriptome analysis revealed a
shift in profile towards healthy control mice, presenting a possible therapeutic strategy.
Furthermore, the gene sets indicated a correlation with IL10RA activation induced by the
inhibition of miR-142-5p, reinforcing its therapeutic utility [58].
While miR-122 inhibition is being evaluated in clinical trials to combat Hepatitis C
virus (HCV) infections using the antimir Miravirsen which inhibits miR-122-HCV mRNA
interaction [173,174], the miRNA’s role has also been assessed in IBD. In epithelial cells
(HT-29), LPS (500 ng/mL LPS, 16 h) induced apoptosis, and NOD2-mediated NFκB ac-
tivation was repressed by pre-treatment with pre-miR-122 for 2 h, as miR-122 directly
targeted the 3′ UTR of NOD2 mRNA [175]. In another study, Selenium-binding protein
1 (SBP1), which is upregulated in inflamed mucosal biopsies of CD patients, was shown
to be a direct target of miR-122-5p [121]. Oxidative stress directly affects SBP1 mRNA
expression and inversely affects miR-122 expression in HT-29 cells. In a TNBS-induced
colitis model (BALB/c mice, 3 mg in 100 µL of 50% ethanol, administered transrectally)
treatment with pre-miR-122 (dose: 5 mg/kg, 12 h after TNBS induction, mice killed on
day 3) alleviated inflammation as seen by the reduction in pro-inflammatory cytokines,
oxidative stress-related proteins and p65NF-κB signaling affected by oxidative stress NFκB.
In vitro studies further showed that oxidative stress causes the hypermethylation of the
promoter region of miR-122, thereby affecting its expression [121].
The colon of IBD patients has been shown to overexpress Substance P (SP), a neu-
ropeptide that interacts with NK-1R and stimulates miR-31-3p in NK1R-overexpressing
colonic epithelial cells (NCM460-NK-1R cells) via the JNK pathway [122]. NCM460-NK-1R
cells, when transfected using the siPORT™ NeoFX lipid transfection system with antisense-
miR-31-3p, showed an increase in pro-inflammatory mRNAs CCL2 and IL-6. In contrast,
miR-31-3p mimics caused a reduction in these cytokine mRNAs in addition to TNFα and
IL-1β mRNAs, depicting the miRNAs’ role in negatively regulating pro-inflammatory
cytokines in colonic cells. Consequently, inflamed UC colons were shown to express higher
levels of miR-31-3p than control samples. Likewise, higher expression was observed in
the epithelial layer of colons of 2% DSS (5 days)- and TNBS (intracolonic 80 mg/kg TNBS
in 30% ethanol on day 1, colon tissue harvested on day 7)-treated male C57BL/6J mice.
Despite the higher colonic levels of miR-31-3p, when LNA-as-miR-31-3p was administered
intracolonically (dose: 40 µg, on days 1, 3, and 5 of DSS induced-colitis, and days 2, 4,
and 6 of TNBS induced colitis), it exacerbated colitis disease outcome. The group then
investigated the effects of overexpression of miR-31-3p in a DSS-induced colitis model by
intracolonic administration of agomirs (dose: 80 µg) and found it to alleviate colitis as seen
by the reduction in colonic immune cell infiltration, TNFα, CXCL10 and CCL2 mRNA, and
improvement in the histopathology score. Target analysis revealed that miR-31-3p targets
RhoA, which is implicated in intestinal inflammation, showing that the overexpression of
miR-31-3p downregulates RhoA expression, thereby reducing inflammation [122].
Together, these data indicate how mouse models of IBD, in conjunction with patient-
derived data and samples, have helped nominate several miRNAs for therapeutic use, with
some candidates (e.g., ABX464) progressing to clinical trials.
5. Exosome-Aided Communication
Exosomes are extracellular vesicles (EVs) originating from the endosomal system and
are 50–150 nm in diameter [176]. These nanovesicles are secreted by cells in healthy and
pathological conditions; consequently, they can be of diagnostic utility as they depict the
state of the cells from which they originate. It is also increasingly being recognized that
EVs can be leveraged as vehicles to transport fragile payloads such as nucleic acids, as
they can be relatively easily manipulated either after isolation or endogenously during
their genesis. Moreover, EVs are stable, offering the advantage of being well tolerated
in the host [177,178]. Exosomes are enriched in ncRNA, especially miRNA, as well as
mRNAs, proteins, and lipids, bringing about gene regulation [179]. Indeed, exosomes
provide important regulatory signals to recipient cells. Since the gut is home to many cell
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types and the microbiota, EVs provide a means to maintain intestinal homeostasis [179]. In
IBD patients, EVs from the intestinal lumen are abundant in pro-inflammatory mRNAs,
and the stability of the payload indicates potential utility as biomarkers to assess intestinal
mucosal health [180]. Here, we summarize some recent studies that delved into or utilized
miRNA-loaded EVs in cell culture experiments and in animal models of colitis.
Endogenous manipulation of EVs during their biogenesis enables the enrichment
of a particular miRNA. As discussed above, miR-146a mimics can be utilized in IBD for
their anti-inflammatory properties. Wu et al. produced EVs by transfecting bone marrow-
derived stem cells (BMSCs) with recombinant lentivirus, containing miR-146a plasmid and
growing these cells until passage 5 [181]. Later, the culture supernatants were purified,
and the isolated EVs characterized for miR-146a enhancement, morphology, and surface
epitome proteins [181]. The authors tested the miR-146a-EVs in a TNBS Sprague Dawley
rat model by injecting 100 µg per rat of the EVs resuspended in 1 mL PBS through the
tail vein on the third day of TNBS enema [181]. Colonic analysis of miR-146a expression
revealed higher expression following miR-146a-EV treatment, compared to control EVs,
and improved the disease activity index. Furthermore, there was a reduction in the levels
of pro-inflammatory cytokines and an improvement in the tissue morphology. Validated
miR-146a targets in NFκB signaling—TRAF6 and IRAK1—were suppressed following
miR-146a-EV treatment, further bolstering the utility of miR-146a-EVs [181].
Serum exosomes are being explored for diagnostic utility since, compared to tis-
sue biopsies, they are easy to collect from patients. In addition, their payloads are ex-
pected to lend novel insight into disease pathogenesis and mechanisms and tracking
their biodistribution could facilitate their use as delivery vehicles. A recent study ex-
plored serum exosomes from CD patients (CD-exo) for their role in aggravating intestinal
inflammation and barrier disruption [182]. CD patients had a significantly higher num-
ber of exosomal RNAs than healthy volunteers (Ctrl-exo). Upon isolation, when these
serum-derived CD-exo were labeled with the fluorescent dye DiR (1,1-dioctadecyl-3,3,3′3′-
tetramethylindotricarbocyanine-iodide) and injected IP into mice, they made their way
to the intestines. Next, to probe the effects of these CD-exo on inflammation and barrier
disruption, the authors treated RAW 264.7 and Caco-2 cells with either CD-exo or Ctrl-exo.
They observed that CD-exo-treated RAW 264.7 cells showed the significant upregulation of
pro-inflammatory cytokines TNFα and IL-6, compared to Ctrl-exo-treated cells. In Caco-2
monolayers, they observed a loss in barrier function, as shown by the reduced TEER values
and an increase in fluorescein isothiocyanate (FITC) dextran (4 kDa) permeability from the
apical to the basal side of the monolayers. Furthermore, in DSS-treated mice (2.5% DSS), the
IP administration of CD-exo (dose: 200 ug/mouse, every 48 h during DSS colitis model es-
tablishment for seven days) worsened colitis compared to both healthy mice and DSS-mice
treated with Ctrl-exo, suggesting that CD-exo indeed have a deleterious effect on colitis
that could be mediated by their role in propagating excessive inflammation and barrier
disruption. To elucidate why CD-exo aggravate colitis, the team investigated the exosomal
content from the sera of healthy and mild-severe CD patients using miRNA sequence anal-
ysis, which revealed 82 differentially expressed miRNAs between the two groups. Among
them, let-7b-5p expression correlated inversely with CD disease severity when the CD
group was divided into mild and severe. When transfecting LPS (100 ng/mL, 24 h)-treated
RAW 264.7 cells, they observed that let-7b-5p mimics CD-exo (transfected for 48 h via
electroporation) and reduces proinflammatory cytokines by dampening the TLR4/NFκB
signaling pathway suggesting let-7b-5p’s role in alleviating inflammation via macrophage
polarization. Next, the group exploited CD-exo as a vehicle to target the intestine in mice
and modified them to contain let7b-5p mimics. Upon IP injection in DSS-treated mice, the
let7b-5p mimics loaded in CD-exo significantly relieved colitis, as seen by the improvement
in body weight and mucosal tissue damage [182]. Taken together, these data reveal the
differential expression of let-7b-5p in serum CD-exo compared to Ctrl-exo, as well as the
utility of let-7b-5p mimics in alleviating inflammation.
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6. Host–Microbiota Interactions Can Impact IBD Via Modulating miRNA
Dysbiosis, a reduction in microbial diversity, is a hallmark of IBD, underscoring the
role of the microbiome in maintaining mucosal homeostasis. Thus, an emerging field of
research involves the role of miRNAs in IBD through host–microbiome interactions, and
the future is promising with studies aimed at using miRNAs as disease biomarkers and
at leveraging probiotics as a treatment. The host–microbiome interactions are bidirec-
tional, where the host immune system can shape the microbiome, and the microbiome
affects the host transcriptome [183]. Global microRNA expression profiling of the cecal
transcriptome of germ-free and specific pathogen-free Swiss Webster mice revealed at least
eighteen differentially expressed miRNAs [184]. These miRNAs are potential gene regula-
tors of the innate and adaptive immune systems, and some have been implicated in the
pathogenesis of IBD [185]. In patients with CD, the miRNA profile is differential between
affected and non-affected mucosa tissue [186]. Interestingly, communication between
the host and the microbiome is enabled through EVs, and the health of the interaction
can be assessed by intestinal EVs [187]. A recent study explored how adherent-invasive
E. coli (AIEC) that atypically colonize the intestinal mucosa of CD patients replicate in
cells receiving exosomes from AIEC-infected intestinal cells [188]. The authors found that
AIEC-infected intestinal cells secrete exosomes taken up by the surrounding macrophages,
triggering an inflammatory response. Upon further analysis, the authors noticed that the
exosomes were enriched in miR-130a and miR-30c that target autophagy mRNAs ATG5
and ATG16L1, promoting AIEC to thrive in recipient cells, including macrophages [188].
To test an intervention to promote autophagy by suppressing miR-130a and miR-30c, the
group transfected the human adherent colon cancer cell line T84 with either anti-miR-130a
and anti-miR-30c together or non-coding (NC) controls, using Lipofectamine 2000 for
24 h, and then infected the cells with AIEC for 12 h. Treatment with anti-miR-130a and
anti-miR-30c significantly reduced the levels of miR-130a and miR-30c compared to NC
controls. Furthermore, the inhibition of these miRNAs significantly increased the levels of
ATG5 and ATG16L1. It also abolished the proliferation of AIEC [188], suggesting that the
inhibition of miR-130a and miR-30c in IECs could be a potential therapeutic strategy to
restrict AIEC proliferation in CD patients.
7. Conclusions
miRNA has been extensively investigated in many diseases for both its diagnostic
and therapeutic utility. In both UC and CD, miRNA can help us understand pathogenesis
and to develop novel therapeutic strategies. Recent studies have provided insights into
how endogenous miRNA and EVs can be manipulated in vitro and in vivo to alleviate
disease symptoms. These studies also allow us to appreciate the strong association between
miRNA levels and disease phenotypes in various mouse models. Notably, characteristics
that define UC and CD are regulated at the miRNA level, including the loss of barrier
integrity and immune system dysregulation. Some of these effects can be mediated via EVs,
which have been shown to contribute to disease severity. Further defining the intricate
networks of miRNA and the genes they regulate will be vital for advancing progress
towards interventions that effectively alleviate disease symptoms and maintain remission.
Specifically, since miRNA-based combinatorial cancer therapy has shown some promise in
oncology, it is likely that a similar combinatorial approach—miRNA therapeutics, together
with existing therapeutics, such as aminosalicylates, anti-TNFα inhibitors, corticosteroids,
and newer biologic therapies (Vedolizumab and Ustekinumab)—might be beneficial for the
prevention of IBD, as well as to avoid recurrence or the loss of response to current therapies.
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141. Béres, N.J.; Szabó, D.; Kocsis, D.; Szűcs, D.; Kiss, Z.; Müller, K.E.; Lendvai, G.A.; Kiss, A.; Arato, A.; Sziksz, E.; et al. Role of
Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease. Inflamm. Bowel
Dis. 2016, 22, 327–335. [CrossRef] [PubMed]
142. Anzola, A.; González, R.; Gámez-Belmonte, R.; Ocón, B.; Aranda, C.J.; Martínez-Moya, P.; López-Posadas, R.; Hernández-
Chirlaque, C.; De Medina, F.S.; Martínez-Augustin, O. miR-146a regulates the crosstalk between intestinal epithelial cells,
microbial components and inflammatory stimuli. Sci. Rep. 2018, 8, 17350. [CrossRef] [PubMed]
143. Boldin, M.P.; Taganov, K.D.; Rao, D.; Yang, L.; Zhao, J.L.; Kalwani, M.; Garcia-Flores, Y.; Luong, M.; Devrekanli, A.; Xu, J.; et al.
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J. Exp. Med. 2011, 208, 1189–1201.
[CrossRef]
144. Lu, L.-F.; Boldin, M.; Chaudhry, A.; Lin, L.-L.; Taganov, K.D.; Hanada, T.; Yoshimura, A.; Baltimore, D.; Rudensky, A.Y. Function
of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 Responses. Cell 2010, 142, 914–929. [CrossRef]
145. Yang, L.; Boldin, M.; Yu, Y.; Liu, C.S.; Ea, C.-K.; Ramakrishnan, P.; Taganov, K.D.; Zhao, J.L.; Baltimore, D. miR-146a controls the
resolution of T cell responses in mice. J. Exp. Med. 2012, 209, 1655–1670. [CrossRef]
146. Tourkochristou, E.; Aggeletopoulou, I.; Konstantakis, C.; Triantos, C. Role of NLRP3 inflammasome in inflammatory bowel
diseases. World J. Gastroenterol. 2019, 25, 4796–4804. [CrossRef] [PubMed]
147. Bauernfeind, F.; Rieger, A.; Schildberg, F.A.; Knolle, P.A.; Schmid-Burgk, J.; Hornung, V. NLRP3 Inflammasome Activity Is
Negatively Controlled by miR-223. J. Immunol. 2012, 189, 4175–4181. [CrossRef] [PubMed]
Cells 2021, 10, 2204 32 of 33
148. Johnnidis, J.B.; Harris, M.H.; Wheeler, R.T.; Stehling-Sun, S.; Lam, M.H.; Kirak, O.; Brummelkamp, T.R.; Fleming, M.; Camargo,
F.D. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008, 451, 1125–1129.
[CrossRef]
149. Roffel, M.P.; Bracke, K.R.; Heijink, I.H.; Maes, T. miR-223: A Key Regulator in the Innate Immune Response in Asthma and COPD.
Front. Med. 2020, 7. [CrossRef] [PubMed]
150. Chen, S.-Y. MicroRNA-223: A double-edged sword in rheumatoid arthritis. Rheumatol. Int. 2013, 34, 285–286. [CrossRef]
151. Yan, L.-N.; Zhang, X.; Xu, F.; Fan, Y.-Y.; Ge, B.; Guo, H.; Li, Z.-L. Four-microRNA signature for detection of type 2 diabetes. World
J. Clin. Cases 2020, 8, 1923–1931. [CrossRef]
152. Sánchez-Ceinos, J.; Rangel-Zuñiga, O.A.; Clemente-Postigo, M.; Podadera-Herreros, A.; Camargo, A.; Alcalá-Diaz, J.F.; Guzmán-
Ruiz, R.; López-Miranda, J.; Malagón, M.M. miR-223-3p as a potential biomarker and player for adipose tissue dysfunction
preceding type 2 diabetes onset. Mol. Ther. Nucleic Acids 2021, 23, 1035–1052. [CrossRef]
153. Krausgruber, T.; Blazek, K.; Smallie, T.; Alzabin, S.; Lockstone, H.; Sahgal, N.; Hussell, T.; Feldmann, M.; Udalova, I. IRF5
promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 2011, 12, 231–238. [CrossRef]
154. Weiss, M.; Blazek, K.; Byrne, A.J.; Perocheau, D.P.; Udalova, I.A. IRF5 is a specific marker of inflammatory macrophages in vivo.
Mediat. Inflamm. 2013, 245804. [CrossRef]
155. Kühn, R.; Löhler, J.; Rennick, D.M.; Rajewsky, K.; Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993,
75, 263–274. [CrossRef]
156. Chaudhuri, A.A.; So, A.Y.-L.; Sinha, N.; Gibson, W.S.J.; Taganov, K.D.; O’Connell, R.M.; Baltimore, D. MicroRNA-125b Potentiates
Macrophage Activation. J. Immunol. 2011, 187, 5062–5068. [CrossRef]
157. Chaudhuri, A.; So, A.S.; Baltimore, D.; O’connell, R.M. Regulation of macrophage activation using miR-125b. WO2012177565,
2014.
158. Sugimoto, K. Role of STAT3 in inflammatory bowel disease. World J. Gastroenterol. 2008, 14, 5110–5114. [CrossRef] [PubMed]
159. Koukos, G.; Polytarchou, C.; Kaplan, J.L.; Morley–Fletcher, A.; Gras-Miralles, B.; Kokkotou, E.; Baril–Dore, M.; Pothoulakis, C.;
Winter, H.S.; Iliopoulos, D. MicroRNA-124 Regulates STAT3 Expression and Is Down-regulated in Colon Tissues of Pediatric
Patients with Ulcerative Colitis. Gastroenterology 2013, 145, 842–852. [CrossRef] [PubMed]
160. Xiao, Y.-T.; Wang, J.; Lu, W.; Cao, Y.; Cai, W. Downregulated expression of microRNA-124 in pediatric intestinal failure patients
modulates macrophages activation by inhibiting STAT3 and AChE. Cell Death Dis. 2016, 7, e2521. [CrossRef]
161. Sun, Y.; Qin, Z.; Li, Q.; Wan, J.-J.; Cheng, M.-H.; Wang, P.-Y.; Su, D.-F.; Yu, J.-G.; Liu, X. MicroRNA-124 negatively regulates
LPS-induced TNF-α production in mouse macrophages by decreasing protein stability. Acta Pharmacol. Sin. 2016, 37, 889–897.
[CrossRef]
162. Vermeire, S.; Hébuterne, X.; Napora, P.; Wisniewska-Jarosinska, M.; Kiss, G.; Bourreille, A.; Przemysław, Z.; Nitcheu, J.; Gineste,
P.; Steens, J.-M.; et al. OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients. J. Crohn’s
Coliti 2019, 13, S014–S015. [CrossRef]
163. Tazi, J.; Begon-Pescia, C.; Campos, N.; Apolit, C.; Garcel, A.; Scherrer, D. Specific and selective induction of miR-124 in immune
cells by the quinoline ABX464: A transformative therapy for inflammatory diseases. Drug Discov. Today 2020, 26, 1030–1039.
[CrossRef]
164. Chebli, K.; Papon, L.; Paul, C.; Garcel, A.; Campos, N.; Scherrer, D.; Ehrlich, H.J.; Hahne, M.; Tazi, J. The Anti-Hiv Candidate
Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages. Sci. Rep. 2017, 7, 4860.
[CrossRef]
165. Zhang, J.; Lian, B.; Shang, Y.; Li, C.; Meng, Q. miR-135a Protects Dextran Sodium Sulfate-Induced Inflammation in Human
Colorectal Cell Lines by Activating STAT3 Signal. Cell. Physiol. Biochem. 2018, 51, 1001–1012. [CrossRef] [PubMed]
166. Takahashi, H.; Kanno, T.; Nakayamada, S.; Hirahara, K.; Sciume, G.; Muljo, S.; Kuchen, S.; Casellas, R.; Wei, L.; Kanno, Y.; et al.
TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat.
Immunol. 2012, 13, 587–595. [CrossRef]
167. Xue, X.; Feng, T.; Yao, S.; Wolf, K.; Liu, C.-G.; Liu, X.; Elson, C.O.; Cong, Y. Microbiota Downregulates Dendritic Cell Expression
of miR-10a, Which Targets IL-12/IL-23p40. J. Immunol. 2011, 187, 5879–5886. [CrossRef]
168. Wu, W.; He, C.; Liu, C.; Cao, A.T.; Xue, X.; Evans-Marin, H.L.; Sun, M.; Fang, L.; Yao, S.; Pinchuk, I.V.; et al. miR-10a inhibits
dendritic cell activation and Th1/Th17 cell immune responses in IBD. Gut 2014, 64, 1755–1764. [CrossRef] [PubMed]
169. Zeng, J.; Zhang, D.; Wan, X.; Bai, Y.; Yuan, C.; Wang, T.; Yuan, D.; Zhang, C.; Liu, C. Chlorogenic Acid Suppresses miR-155 and
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